| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | isonicotinohydroxamic acid | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |